 |
|
|
| |
Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxilfumarate regimens to the single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofoviralafenamide(D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults through 24 weeks: EMERALD Study
|
| |
| |
Reported by Jules Levin
M, et al. 9th IAS2017. July 23-16 Paris, France
Jean-Michel Molina1, Joel Gallant2, Chloe Orkin3, Eugenia Negredo4, Laveeza Bhatti5, Joseph Gathe6, Erika Van Landuyt7, Erkki Lathouwers7, Veerle Hufkens7, Simon Vanveggel7, Magda Opsomer7
1Department of Infectious Diseases, St-Louis Hospital, University of Paris Diderot, Paris, France; 2Southwest CARE Center, Santa Fe, New Mexico, USA; 3Barts and Health NHS Trust, London, UK; 4Germans TriasiPujolUniversity Hospital, Badalona, Spain; 5AIDS Healthcare Foundation, Beverly Hills, California, USA; 6Therapeutic Concepts, Houston, Texas, USA; 7Janssen PharmaceuticaNV, Beerse, Belgium
|
| |
|
|
|
|
|
